Cargando…
Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents
The overexpression of P-glycoprotein (P-gp/ABCB1), an ATP-binding cassette (ABC) drug transporter, often contributes to the development of multidrug resistance (MDR) in cancer cells. P-gp mediates the ATP hydrolysis-dependent efflux of a wide range of chemotherapeutic agents out of cancer cells, the...
Autores principales: | Wu, Chung-Pu, Murakami, Megumi, Wu, Yu-Shan, Chi, Ya-Chen, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Ambudkar, Suresh V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326665/ https://www.ncbi.nlm.nih.gov/pubmed/34350184 http://dx.doi.org/10.3389/fcell.2021.699571 |
Ejemplares similares
-
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
por: Catlett, Ian M., et al.
Publicado: (2020) -
The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2019) -
Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein
por: Sajid, Andaleeb, et al.
Publicado: (2020) -
Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023) -
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
por: Gillooly, Kathleen M., et al.
Publicado: (2017)